PPD Opens Vaccine Clinical Research Center In Taizhou: One Step Closer To Its Goal To Become China's Number One Service Provider
This article was originally published in PharmAsia News
SHANGHAI - PPD has been touting the opening of its new Vaccines and Biologics Center of Excellence in Wayne, Pennsylvania, and now the company is pushing its vaccine expansion into China with the launch of a vaccine clinical research center in Taizhou China Medical City
You may also be interested in...
SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago
Charles River's acquisition of WuXi PharmaTech, valued at $1.6 billion, is the largest merger so far in China's healthcare space and is likely to drastically change the CRO playing field in China
PPD Continues High-speed Expansion In Asia With Second Acquisition Of A China-based CRO This Quarter
BEIJING - As part of a rapid-fire expansion across Asia, the U.S.-headquartered PPD has outlined plans to purchase and merge with the Beijing-based contract research organization BioDuro